Asthma Clinical Trials

Find Asthma Clinical Trials Near You

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of GB-0895 Adjunctive Therapy in Adults and Adolescents With Severe Uncontrolled Asthma

Status: Recruiting
Location: See all (96) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 3
SUMMARY

The objective of this study is to assess the potential for GB-0895 treatment to improve the health of adolescents and adults with severe asthma that is uncontrolled by inhaled corticosteroids (ICS) and conventional asthma controllers. The study details include: Study treatment: randomized to receive either GB-0895 or placebo administered every 6 months over 52 weeks. Visit frequency: every 1-2 months after the first month.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 12
Maximum Age: 80
Healthy Volunteers: f
View:

• Adults and adolescents ≥ 12 and ≤ 80 years of age.

• Documented physician diagnosis of asthma for ≥ 2 years.

• Subjects must be on medium to high dose ICS for ≥ 12 months before Screening Visit 1 plus at least 1 additional asthma controller (e.g., LABA, LAMA) ≥ 3 months before Screening Visit 1 with no change in ICS or controller(s) for at least three months.

• Subjects must have a well-documented history of at least two asthma exacerbations requiring systemic corticosteroid treatment despite the use of medium-to-high dose ICS in the past 12 months before Screening Visit 1.

• Adults ≥ 18 years of age at Screening Visit 1, a pre-BD FEV1 \<80% predicted at Screening Visit 1.

• Adolescents 12 to \< 18 years of age at Screening Visit 1: A pre-BD FEV1 \< 90% predicted OR, FEV1:Forced Vital Capacity (FVC) ratio \< 0.80.

• Positive BD responsiveness test: Increase of at least 12% and 200 mL in FEV1 between 15 and 60 minutes after the administration of a short-acting β2-agonist (SABA) at least once during the screening period.

• ACQ-6 score ≥ 1.5 at the Screening Visit.

• Weight ≥40 kg at the Screening Visit 1

Locations
United States
California
Research Site 13
RECRUITING
Bakersfield
Research Site 12
RECRUITING
Inglewood
Research Site 65
RECRUITING
Lancaster
Research Site 10
RECRUITING
West Covina
Florida
Research Site 03
RECRUITING
Miami
Research Site 06
RECRUITING
Miami
Research 09
RECRUITING
Orlando
Research Site 01
RECRUITING
Tamarac
Research Site 04
RECRUITING
Tampa
Research Site 05
RECRUITING
Tampa
Massachusetts
Research Site 20
RECRUITING
Fall River
Michigan
Research Site 02
RECRUITING
Ypsilanti
New York
Research Site 69
RECRUITING
New York
Research Site 69
RECRUITING
New York
Ohio
Research Site 11
RECRUITING
Dayton
Oklahoma
Research Site 21
RECRUITING
Oklahoma City
South Carolina
Research Site 16
RECRUITING
Rock Hill
Texas
Research Site 17
RECRUITING
San Antonio
Research Site 07
RECRUITING
Sugar Land
Virginia
Research Site 08
RECRUITING
Williamsburg
Other Locations
Argentina
Research Site 67
RECRUITING
Buenos Aires
Research Site 31
RECRUITING
Ciudad Autónoma De Buenos Aires
Research Site 33
RECRUITING
Ciudad Autónoma De Buenos Aires
Research Site 79
RECRUITING
Ciudad Autónoma De Buenos Aires
Research Site 87
RECRUITING
Ciudad Autónoma De Buenos Aires
Research Site 92
RECRUITING
Ciudad Autónoma De Buenos Aires
Research Site 81
RECRUITING
Concepción Del Uruguay
Research Site 80
RECRUITING
Mendoza
Research Site 100
RECRUITING
San Miguel De Tucumán
Australia
Research Site 72
RECRUITING
Coffs Harbour
Research site 39
RECRUITING
Southport
Belgium
Research Site 45
RECRUITING
Erpent
Research Site 22
RECRUITING
Mechelen
Research Site 73
RECRUITING
Mechelen
Estonia
Research Site 101
RECRUITING
Tartu
Research Site 95
RECRUITING
Tartu
France
Research Site 53
RECRUITING
Brest
Italy
Research Site 99
RECRUITING
Trieste
Japan
Research site 40
RECRUITING
Chuo Ku
Research Site 54
RECRUITING
Chuo Ku
Research Site 55
RECRUITING
Ebino
Research Site 32
RECRUITING
Fukui-shi
Research Site 15
RECRUITING
Fukuoka
Research Site 75
RECRUITING
Hachioji-shi
Research Site 41
RECRUITING
Himeji
Research Site 37
RECRUITING
Isesaki-shi
Research Site 66
RECRUITING
Itabashi-ku
Research Site 46
RECRUITING
Kiyose-shi
Research Site 23
RECRUITING
Matsuyama
Research Site 34
RECRUITING
Niigata
Research Site 47
RECRUITING
Niigata
Research Site 42
RECRUITING
Sakai
Research Site 68
RECRUITING
Seto-shi
Research Site 14
RECRUITING
Shinagawa-ku
Research Site 86
RECRUITING
Toshima-ku
Research Site 38
RECRUITING
Ube
Research Site 63
RECRUITING
Uruma
Research Site 43
RECRUITING
Yokohama
Serbia
Research Site 19
RECRUITING
Belgrade
Research Site 51
RECRUITING
Belgrade
Research Site 57
RECRUITING
Belgrade
Research Site 58
RECRUITING
Belgrade
Research Site 56
RECRUITING
Kamenitz
Research Site 89
RECRUITING
Novi Sad
Slovakia
Research Site 36
RECRUITING
Košice
Research Site 35
RECRUITING
Spišská Nová Ves
Spain
Research Site 59
RECRUITING
Barcelona
Research Site 71
RECRUITING
Zaragoza
Turkey
Research Site 93
RECRUITING
Ankara
Research Site 78
RECRUITING
Antalya
Research Site 77
RECRUITING
Trabzon
Ukraine
Research Site 49
RECRUITING
Chernivtsi
Research Site 91
RECRUITING
Ivano-frankivsk
Research Site 44
RECRUITING
Kyiv
Research Site 52
RECRUITING
Kyiv
Research Site 74
RECRUITING
Kyiv
Research Site 76
RECRUITING
Kyiv
Research Site 82
RECRUITING
Kyiv
Research Site 64
RECRUITING
Lutsk
Research Site 50
RECRUITING
Vinnytsia
Research Site 60
RECRUITING
Vinnytsia
Research Site 61
RECRUITING
Vinnytsia
Research Site 83
RECRUITING
Vinnytsia
United Kingdom
Research Site 28
RECRUITING
Bristol
Research Site 18
RECRUITING
High Wycombe
Research Site 85
RECRUITING
Honiton
Research Site 26
RECRUITING
London
Research Site 30
RECRUITING
London
Research Site 62
RECRUITING
London
Research Site 70
RECRUITING
Metropolitan Borough Of Wirral
Research Site 27
RECRUITING
Nottingham
Research Site 48
RECRUITING
Plymouth
Research Site 29
RECRUITING
Romford
Research Site 24
RECRUITING
Rotherham
Research Site 84
RECRUITING
Somerton
Research Site 25
RECRUITING
Thetford
Contact Information
Primary
Generate Recruitment
solairiastudy@generatebiomedicines.com
888-469-0033
Time Frame
Start Date: 2026-01-20
Estimated Completion Date: 2029-01
Participants
Target number of participants: 786
Treatments
Experimental: GB-0895
GB-0895 Subcutaneous (SC) injection
Placebo_comparator: Placebo
Placebo Subcutaneous (SC) injection
Related Therapeutic Areas
Sponsors
Leads: Generate Biomedicines

This content was sourced from clinicaltrials.gov